Erratum: Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE and Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013;119:3788-96

Errata

This article corrects:

  1. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL) Volume 119, Issue 21, 3788–3796, Article first published online: 6 August 2013

The authors noticed an error in the Materials and Methods section, second paragraph, which describes the ofatumumab dose.

The ofatumumab dose was not based on body surface area and the first sentence should read “…ofatumumab (cycle 1: 300 mg on day 1, 1000 mg on day 2; cycles 2–6: 1000 mg on day 1) given intravenously every 21 days.”

The authors regret this error.

Ancillary